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SexuaHv transmitted diseases in adolescence 
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Abstract 
High rates of unprotected sexual behavior in adolescent;; 
result ln rniUio:as of sex.t;.ally trar:~,mitted disea..'\es (S't'T>s) in 
the world. This paper reviews factors inducing high STD 
rates, specific STD\ and their ma:nagement based on 2010. 
US Centers for Disease and Prevention (CDC) STD 
guidelines. Clinicians should screen all their s~xually active 
adolescent patient$ [i).t STDs a::.td prov ide prc,..'entivc 
educatiqn a~ well as tn:atment measures. 
Kejo·word!i: Adolescence, sexu~lly transmitted dise-ases, 
STD 
Intn~du.ction 
There are many sexually transmitted diseases (STDs), 
wbkh can i.nlect adolescents (see- Table 1) (l-5). 
Sexually active adolescents arc at risk for STDs due 
to th6r high rates of sexual a(;tivity, multiple sex 
partners, immatw.'e cervix (cervical ectropion which is 
a good med·ia for gmwth of s.ome STD \igents), other 
high risk behaviors that crrcourage sexual behavior 
(i.e. , substance abuse; hocly piercing; tattoqs), mistrust 
of adults in general, problems traversing the tnGdkal 
system, and an often pervasive belief ("magical 
thinking'') that they are not sqsceptib1e for acquiring 
STDs. The growth of social networks in the past 20 
years has led to another avenue fur allo\oving youth to 
meet. and acq uire STDs. Adolescents receive limited 
$exua1 ~ducation in the United States, have .accidental 
or irregular sexual relationships, change sexual 
part.'1t.."Ts ("serial monogarny"), and tail to use 
condoms on a regular basis. 
The result is that 1 9 million STDs are acquired in 
the United Siates each year, mainly in the 14 to 29 
year old age group. One in six sexually active 
adolescents (15 to 19 years of age) acquires an STD 
each ye<Jr, and one in three persons acquire an STD by 
age 24 years. Those at the highest risk. for an STD 
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include runaway youth, those tTIV(.i!ved fn survival sex 
(prostitmion), those in jails or detention centers, those 
involved in u1ale hom•Jscxuat activity, and youih w:ith 
a history of .STDs. The most .common ST.Ds amun.g 
youth arc infections due to hu:man papillomavirus 
(HPV (6-9), herpes simplex. virus (HSV (10,1 1)), 
chlamydia trachomatis (12,13), neisseria gononhe<le 
(14) and trichomonas vaginalis 1.5-19). The highest 
rates of chlamydia! ?.mi gonococcal init~dions are in 
i 5 to 19- year old fem<.~les, while HPV a(;quisition is 
often during adolescence. Oral ~exual hdJ.avior is 
noted in one-third to one·half pfyouth and can lead to 
the acquisition of various STDs including HPV, 
herpes simplex virus (HSV)., syphili~, gonorrhea, and 
others. Clinicians should note that Neisseria~ 
g(morrhoeae is part of the differential diagnosis of 
pharyngitis in adolescents (see Table 2) and th,is, 
questions about oral :;ex-nal behavior are important 
c~ven when snre throat is the on1y presentation. 
T:tblc L STU ,-\gmHs (Diseases w: Jnfections; STDs; STili) 
r· H;;;.~~ Papil;:;;;;;;;~irus (HPV) ............. --......... ---.. ·r-il~patitis A, H: .. E· .. ·-. _ ........ --.- .......... - .............. --, 
! Trichomonas vagina/is : l!aemophilt<.s decreyi (Chancre:d) 
1 Chlamydia irachommls i Pediculost.;· pubis 
I Neisseria g-:morrhoeae 1: Sarcoptes scabiei (scabies) . ~-!erpes ~irnple.-::_ viru..~ .CHPV). . , Gardne:ella va/?tnalis (Bacterial. Vaginosis) 
i tli:m)an tmmunodeficwncy Vlf'I.IS (HI\·) ' (Sexually assocmted) 
i Treponen;a pafli(iwn (syphWs) Klehsi!ilia granulamatis (Lymphogranuloma venereum) 
I. Molloscum {:ontagiosurn Behc~et's dhease i Donovania granulomatis (Granuioma .ingpinale) Reit.::r's .syndrome 
i Others 
[ 
i 
I 
i , ___ ....... .. ... ___ ........ ----"--· ""'-----......... __ ....... ---~· ____ ........ ...~ 
T.ahle 2. Differential Diagnos~s of Exudative, Diffuse, m· M.emb!·iuwlfs Pha.ryngith 
~~~~~e ::::::::==:-·---~~:::::n>-.7". criptt_2~: ____ :=::====·-·--·=::::::: :==: ____ .. :=. i tr~:~!~~.(:.r.l_t -.- ..... :::: :::::: ... ~ 
i Group A B- hemolytic j Exudative, cii.ffuse, or mcmbran.ous typ~. · 0. ther feat11res: ~· 1.2 :n.=·.l.!.·ion U benza1J. ;ine 1 
: Strepmcvca£~ ! stra>vbcrry tongue, tc.nd<!r anterwr cerv1c.al _pe111c;ll;n IM or oral [ 
j l lymphadenopathy, fever, leukocytosis, qysphagia., liild pen(c;Hin, 250 mg, q!d X 10 l 
I 
.
1
' headache. Minimal coryza and cough. P{lSitive throa~ j day!;; .crythrorr:yc.in, 2.50 i 
culture. Scarl~t fever can oc:c:;lr. Can occur w1th i mg, qid x 10 day:. I 
. inkctk>.us mmtonuckosis. J r~efador · '"! 5(' m:~ q·t' ·~ ! ) i ' """ ~)• ~ I • (> U : 
[ : F v iQr{ ..... ·,.,. t1'\n ; 
~.~~Te,.Ji~>u~-~;;m~nucleosis _ .......... ,: Exudative·:·ilim ..  s~~ .. ;;;·;ncmbran_ou,s e;y·tl~~roa. Pe~iodic ! "s·~~~o;~i~:~· 
0 
· ·~r~: ....... __, 
: ,i:pst~:m-Barr v:rus) fever, lymrhadenopath:Y (espe:cJalJy antenor cerv;cal), l ! 
1 
: splenm~~galy~ a~sol~tc iym.phocyt<,sis, po!iti;'e ! i 
1 hcteroptll agg!utmatlot; tc~{ (or other serq;og1c ; i 
I Gon;;~;~~ccalph·~·~·y·;g;·(·~s· ~~~~i~~~:~~~:~~~;~~I~: ;~~ii1:R~~;~ ~~~)~ma oTth~~--........ !I .... Ceft;i;x;~~:··:iS'o mg JM ·::· .... ·i :.·:,'·. 
l. (Ne.i5seria gonorrh.oeae_) oropharynx associ<~tcd with antcrim cervicai tr,~atment fm Chlamydia 
lymphadenc}palhy and hlstory of m.·al sex with an trachomatL;;: SC(O Tabie ;5. 
I. inf~ct~;d ~exuai partner. Often asymptomatic . Pharynx l j 
1 
1nay he the on.ly site nfin:fedlon in 1%-4% of teenager~ b: J 
h ...... --................. _ \Vith r~onorrhea. .. ..... ---l 
I 
AdenGvinJ.s pharyngitis C't)~i.m:ol) ca~~~;· of 1\0~·~i:~~r;;{;'~~x:cal exudati~~--·-.... ·-· Supp~·;~(i~.:e~ · 
pharj'ngitis and nasopha;:yngitis and fo!Hcular ] ,.  
phrJyn.gitis; difft:sc erythema alst.\ noted, with fever, i 
!_,,., ' lf l ! ·~· _ ...,....-...,--··-·· ..... -...... ~9:2~~:.a, ana c9.~P~1. ............... -·---... : ...... ------ l ................ ___ ........... .......~ 
i Acute lymphonodular Raised; whlte or yd!ow lesions >vith surrounding l Supportive. 1: 
! ,.,: "' v ,,·.:' • ·th • ·· "' !' · ~r t ••· ~ h" ·. I 
1 . .. ,l~r~ n.,.1,,s 1 c.ry .crr.a ,,1 ne. }'·)S C·d O. ·p ... rynx. : 
I (coxsackievirus A,n) i i , 
! ne;pmgi~~ ............ ~---·t·'i~~puloves·i~~·iarf~si~;·~~··ic~ding ro \Jlc~;:~t·i·o;Js occu;·~;~lsui)i;ort'i~c . . ......... ----< 
1
1
. (coxsa(;k\evirus A) ! th~ phary~x: Pr~sents ~s a febrHe ilin~ss -often in;he . i 
.---...... .. .............. l~!~~r- t~cn.o:.~~_s an entcro\~!.Hf!:.:l::~? ime1J0~~~-·-· __ .. L... . ............ ___ ..... , 
. ·· ~ ·~ · .................... __________ lillilllil _______________ ~ 
.. ::·:: :·· 
-: :;.· 
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L:i~~~:0;~:::::::~:~:~:~=:~:~::::::·------,·-····n:~~~~IP.:~C~~:~:~:::=::::~:~:~:~::::~:~~:::::~::::~::::~:~::::ri:~~~~in~:~1::::::::::::::::::::::::::::::::~:::::~:::::::::::::::::::; 
i Hand, foot, and mc;ctth Vcsic-lllar and dcer~tive lesions ;n the S·upporlwe. ! 
i disease (coxsackievirus A16) mouth. and pharynx with ve~icdar eruptions ! 
i ever hands and feet. _______ j 
i Postang:na1. sepsis Evidence Gf pharyngeal infection fi;iJo,•;ed E8.\iscci"i)~:·artaerci;fC hacterk Treat- : 
! (f"usiJb:.u~terir:~n'l nect'(Jphartitn by high fever, chH-is~ anterior cet, .. icitis_, rnent invol-Ve~ antibiotics··· pending on 
' ! and Bucteroid:::s sper;ies) multiole abscesses, jaundke, etc. cuiturc results- penicillin, , ! - L· t 
! dindarnvcin. mctronidaznlc. elt:. i 
i Co-;);:~b-:_;~t;.;:;~:;;_-· Variabt'Z;pb~~-;~;.-g}ti~·~;~:;~i-;;t~d with ;-....... , .. r~:~·yt·h;~;;~;;;~;;~~-2-so··;.~~~:··,]i~f~--'['{}-~[-~·);;:----~ 
· scarlatiruf!mll enmtion of arms and legs ! Penicillin not reliable. I 
i:a.'~~~~:::~ _______ ;~~:~;~~~:;iE::,:~::oct·:· J __ . ___ j 
H eprlnted wlth nermission frc,m: Ch:ydarms Dt-:: "Disorders of the ears, eyes, nose. and throat." In: Adolescent Medicine, 
Third Edition, Eds: 
AD Hofmann, DE Greydanus Stamford, CT: Appkwn & Lange, ch. 8: page lOG, 1997. 
Primary prcvemkm of STD~> it1vnlves proper 
(:ounsding of youth regarding STDs (including H IV), 
use of latex condoms for all sexual encounters, and 
immunization with HPV, Hepatitis A, as well as 
Hepatitis B vaccines {including for males having sex 
\Vith men and illicit drug users). 
Use of a condom is a marker for improved risk 
behavior in adolescents and is beneficial in h_;wcring 
STD rates, especially for N gonorrhoeae, C 
irachomatis and HlV, Spermicides with nonoxynoi-9 
are riOt recommctH.l.ed at this time because of their 
failure to prevent various. S'IDs and potential injury to 
the surface of epithelia] cells linked with its usc that 
may enhance the acquisition of HJV. 
Secondary prevention of STDs involves regular 
STD screening of aH sexually active yout:.'1, evaluation 
for STDs, proper treatment of i.demified STDs 
(including asymptomatic infectint1 }, and partner 
notification in the presence of STDs. 
Screening sexur::lly active teenagers and adt1 Its 
indudes annual testing for chbJ.""hydia. tmchomatis (up 
to age 25 years), annual testing for neisscria 
gonorrhoeae if at risk, and annual HIV screening if 
sexuc:.lly active as weB as using injection drugs. Self .. 
collection vaginal swabs and mine samples for C 
tradmmatis and N gonorrhoeae are becoming 
increasingly acceptable to adolescent females. 
One should consult with the CDC 2010 STD 
guide!ines for STD management including STDs in 
special circumstances, such as STDs in pregnancy, 
males having sex with men (MS1vr), &TDs in children, 
women having sex with women, those in correctional 
i.nstitutions, and others. 
Chlamydia trachomatis 
Two species of Chlamydia are recognized: Chlamydia 
psittaci (causing psittacosis) and chlamydia 
trachoma1i.s. The latter consists of different subspecies 
which can cause ccrvldtls, urethritis, trachoma and/or 
lytnpbogranuioma venereum. 
Chlamydia trachomatis is an obligate intracellular 
mictobe which causes the most commonly reported 
bacterial STD in the United States and as noted with 
STDs, is disproportionately increased in minority 
adolescent females. H causes cell da...rnage with a 
significant inflammatory host ceil irntnune response. 
Tw·n to three million infections arc estimated to occur 
each year in the US and the prevalence in 18 to 26 
year olds is nearly 5~·o in females and nearly 4% in 
males. 
Chlamydia trachoma.tis is a bacteria that can 
cause a variety of inJections (Table 3) t..l-Jat include 
cervicitis, urethritis (vvith dysuria, m'ethra! discharge 
[often thin]), epididymitis, proctitis, pharyngitis, 
proctitis, perihepatitis (Fitz-Hugh-Curtis syndrome), 
and endocetvldtis (pelvic infla:nmatory disease--PTD} 
(l2,13), 
AU sexually act~vc females under the age of 25 
years should be screened annmdly for the presence of 
this bacteria that can be silent (asymptornatic) in hJ.lf 
or more of those i11fec!ed. 
A variety of diagnostic tests are available. as 
noted in table 4, Nucleic add mnplifkution testing 
(NAAT) and DNA probes can be done on vaginal or 
cervical material as well as urine, NAAT sensitivity' is 
excellent, in the rage of 87% to 97%, 
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Table 3. Chl;nnydaa '!'.nu:humati~ Infections 
Salpingitis 
Peritonitis 
5. Perihepatitis (Fitz-Hugh--Curtis syndrome) 
6. Urethral syndrome 
(dysuria/urethral sy;1dmme) 
7. Epididymitis 
S. Conjunctivitis 
9. Pharyngitis 
l 0. Otitis media 
i 1 ~ Pnettmonia 
12. Endocarditis 
13. PrGstaliti.& 
14. Proctitis (LGV stain) ! ! 
! 15. ? A!t"hritis 
................ ~ _j 
\ 
! t6. Reiter's syndmme 
! 
l 17. Others .....________ _________ :.,__ _____ _ 
Tabk 4. Dia.gn{lstk Tests fo:r Chlamdia tr::u:homaH.s 
r··--c-en c uh~r·e·(:'&0.id--sii~;,ci;(;;;) 
\ Polymerase cham reaction test (nucle[c 
1 amplification testi11g or NAAT) 
acid 
! Lig~se chait1 reaction test (NAAT) 
i Enzyme-li...'1ked immunoassay (ElA, ELISA) \ 
! Dir:.::et flumes cent anLibod.y (DFA) . i 
\ DNA probes (Gcn .. Probc; (Erect hvb~;d;nition i 
lJ~irt:<:~:~1i0~1-~~.:--~~-~~!.~~~~-~Ar.~~~p-~) , . -"-~ _________ j 
Cervicitis 
This can present m various ways, though there 
typica1ly 1s pun1knt or nmcopurulent cervical 
discharge, vaginal ery1hema, and hypcrirophic 
cervical erosion. Mixo<~d. infections with other STDs 
are common., especially Neisseria gonorrhoeae. 
Treatment of ~::crvlcitis due to Chlamydia traclwmatis 
is outlim~d in Table 5. 
\Vhen diagnosis cannot be conftnned, treatment 
for Neisseria gonorrboeae should be included due to 
the high incidence of coinfections. Azithromycin is 
effec1ive for chlamydiat infections in pregnancy. 
Urethi'itis aiui epididy.mitis 
Urethritis due to chlamydia trachommis usually 
presents \vlth dysuria and a thin or non-pun .. :lent 
urethral dis;;;harge; mucopurulent or pLmdent 
discharge may also be seen. H may be present with 
other STD agents includirlg N gorwrrhoeae, 
ureaplasma urealyticum, or trichmnatis vaginatis. 
Urethritis due to C trachomatis and urcaplasma 
urealyticum have the same cUnical appearance and 
both usually respond to doxycycline or erythromycin. 
1'.1ale methritis may also be due to mycoplasma 
genitalium or herpes simplex virus. A first morning 
void urine evaluation may reveal the presence of T. 
vaginaJis in those -\Vith nongonococcal urethritis 
(NCU). Dysmia associated with pyuria can be due to 
chlamydia trachornatis (urethral syndrome). 
Pharyngitis is uncommon and usually due to N 
gonorrhoeae or herpes simplex virus. Caucasian mates 
with HLA-327 v.·ho develop chlamydia..! urogenital 
infection .may subsequently develop Reitct's 
syndrome. Pelvic id'larnmatory disease, ectopic 
pregmmcy and infertility may occur. The 
recomm.:nded treatment sched1~1e for uncorrtplicatd 
~~hlamydia urethritis is azithromycin (1 gram oraHy in 
a single dose) or doxycycline (100 mg tvvice a day 
orally for 7 days) (s0e Table 5). Azithromycin is 
preferred for those w·ho may be non-adherent due to 
i~s single dosing regimen, while erythromycin may 
lead to non-adherence due to gastrointestinal 
intl>lcrance. Alternative treatments include 
erythromycin base (500 rng orally four times a day for 
7 days), etythromydn ethylsuccinatc (&00 mg oml!y, 
four Lirnes a day for 7 days). of1oxadn (300 tng orally 
tv>'ic:e a day f(w 7 days) or 1evot1oxacir, (500 mg orally 
fc:r 7 days). Doxycycline, ofioxacin, and k:vot1oxacin 
arc contTaindi(:ated in pregnancy, 
Recotnmended regimens for the pregnant patient 
include azithrumycin (l gram orally) or amoxidllin--··--
500 mg orally three times a day 7 days. Altema.tivt~s 
for the pregnant patient include crjthromydn base 
(not estolate) --son mg four times a day orany for 7 
days or 250 mg PO, four times a day for 14 days: 
c.J;:;o, erythromycin ethyisucdnate (400 mg, orally 
f()ur times a day for 14 days or 800 rng tour times a 
day fbr 7 days) can be used. 
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Table 6. Screen adolescents with N gonorrhoeae for C 
trachomatis, trepon~ma pa.llidmn and H1V. Treatment 
should also include coverage tor C trac.hamaris since 
ir is present in. up to 40% of cas.es (Table 4). 
Unfortumrtely, antibiotic resrsta.nce, a phenomenon 
begun in the 20th century, is worsening in the 2lst 
century; this includes resista.rrce to pen.lcillin, 
tetracycline, spectinomycit1, quino1ones, and 
floxacins , Other causes of mal~ \Ucihrhis arc noted 
above onder C tTachomatis. Treatment of 
uncomplicated gonococcal int~~cti.on. \Jf the pharynX is 
with ceftriazone (250 mg intrar1msc.ularly) plus 
a;~ithromycin (1 gram oraHy} or Juxytycline (l 00 n:g 
twice a day for 7 days). 
Table 6. Antibiotit.~ Management of Gonoco~:ca! InfcctiMIS af the Cervix, Urethra, 
or Recuun: (uneomplkatcd} ((:DC STD ( l:uidelines, 2012) 
l. Ceitriaxom-\ 250 mg 1M, one dose, or (if not un option) 
2. Ceflxime, 400 mg, cm;~lly, one dos~·. 
···············-·····························\ 
PLUS (For optiuns 1 pnd 2) 
A:z:ithromycin (1 gram orally in one dose) OR Doxycycline (100 mg oral!y twice H. day-7 days) OR 
3. Az1thromyc:in 2 gram dose 
'"'Options 2 and 3 requir~ ;1 te~t of cl;re one \veek f~-:Jllow ing tnmtrnent 
'hblc 7~ H1agnostk Cdtcria fur Pin (2010 CDC STJJ Guidt!lioes) 
~mal Cri.t-er-:i_a _________ ......... ____ ____ _____ _ .................... -
1 a. Uterine tenderness, N 
\ b. Adnexal tcndeli)e"~· or 
i c. Tenderness on cervical motion:.....-_ _ _ 
r····2·.-Addition~~t-Di·i;ti~---·····-··········-·-·-···-· -··················································-·- - -··············· .. ·· 
: a. Cervical (vaginal) mucopurulent discharge 
l b. Or<l.ltemperature over 101 degrees F (over 38.3 degrees C) 
! 
c. Exainiilation of sdine drop from discharge: see white blood ed ls 
. d. Elevated C-reac:tlve ·proteb 
) e, Elevated eryti1rocyte sedimentation rate 
L ............ f. Positive lal? test f£r C. !E~~~t~~~~_?-~is or N. gon~r::!~~-~~~ .. ~-~-<:!t9.~? ......... -----,-································-
i 3. Specific Cri~criaa . 
! 
l 
! 
! 
·-·-.. ········! 
l 
1 a . Positive biopsy ofendomctrium showirlgendometritis 
L' b. Evidence ofPlD on Japaroscopy · c. ~J.lt:a.sou._:_nd_ - ~t:a. nsvaghal) or MRI shows fallopian t. obes thut al'e thick and filled with fluid; may be fn~e J . .. }}~P5~ m the pelVIs or a Ll.Ebo-ovana~.E~!_mplex. _.................... ·-·-.... - ............................... .. 
·····K~~i~- intermitt~;;:·;;·;;~:;;·;;;~;~···················-···-·- -·· ············································· ···· ··· ·· ·······­
Appcndi~itis 
-············· ················ ··· ·· · ·~ ·~···-~~-1 
Endorne1tiosis 
Ectopic pregnancy 
Gastn)enteritis (as due to Yersinia enterocohtiw or Campylobacterf etus) 
Hcnoch--Sdwnidn ;;yndromc 
Hemolytic-uremic syndrome 
.lnfhurunatory bowel disease 
.Mesenteric lymphadenitis 
Ovarian cyst {with or without torslon or n..tvture) 
Pyelonep.hritis 
I 
Other - ----------·········-···-·-··- --- ----·-··········· .. ·-------- --....: 
.· .· · · . . · · · ·.· · . · .. · · ·. · . · · · ·.·.-- .·.·.·:/lC'& 
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Pelvic inflammatory disease (PllJ i ·' . . .~ 
P!D .is a polymicrobial infection of female genit<>l 
tract that can i.nclud:;: C trachomatis and. N 
gonorrhoeae, th is polymicrobial infection may 
involve such agents found in the vagino-cervical 
endogenous flora ------ such as gardnerclla vaginalis, 
bcta~hcmolytic streptococcus, neisseTia meningitides, 
mycoplasma genitali.um, bacteroides fragiHs, 
streptococcus faccalis ureaplasma urealyticum, 
ha.emophilus infhtenzae, co1if(.)rms (en taro 
brtcteri aceac ), cytornegalovi rt<s, pcptostreptoc~)ccus, 
and other anaerobes (21,22). Screening for and 
management of C trachomat:ls can help to prevent 
PID. Tabl.e 7 notes CDC criteda for PID that revolve 
around lo~,ovcr genital tract inflammation with pelvic 
organ tenderness. ·rable 8 notes the differential 
diagnosis for PID; if PID is clinically severe, consider 
hospitaliz:ation and imaging to look for tubo-ovarian 
abscess. 
Table 9 nCltes. CDC-recommended. treatment 
options that seek to provide polymicrobial antibiotic 
coverage to contain the infection (inc;h1ding 
facu ltative and anaerobic bact~tia) and prevent 
:;equel.ae. In those with mild to moderate disease, or4l 
and intravs~nous therapy are considered equaHy 
effe;,;tivc. For those receiving intravenous antibiotics, 
1V therapy may be stopped after 24 hours of clinical. 
improvement with wntin.uation of doxycycline t(n- 1.4 
days lotal. l V doxycycline iniiJsion can be very 
painful aHd oral doxycycline may thus be preferred. 
Ana.c:robic CDverage should be included in the 
presence of a tubo--ovarian abscess. 
Fitz-Hugh-Curtis syndrome 
The Fitz-Hugh-Curtis Syndrome (perihepatitis) is due 
to inthmmation af the liver capsule after a genital 
infection with neisserla gonorrhoeae or chlamydia 
trachomatis. There m~y or may not be a symptomatic 
genital infection at the time the perihepatitis presents . 
Acute, severe, and knife-like right upper qaa.drant 
pa.(n develops with or without right shoulder pain, 
right costal margin friction rub, and abdominal 
rebound or rigidity. Fever, nausea, emesis, hiccups, 
pleurisy, and pleuri t ic chest pain may also occur. T"he 
erythrocyte scdim(mtation .rate (ESR) b elevated and 
the. liver function tests (LFT) are usually normal, 
t.ho;~gh transient rise -in LFTs has been reported. A 
l ap~ro~cQpy ~vi1! usually clemonstra.te the perihepatic 
intlammation and/or prese-nce of the adhesions 
between the anterior abdom:inal waH and the J.iyer, 
Must acute castls will have a positive cervical culture 
for gonorrhea or chlamydia. The liver enzymes (if 
cJc.vatcd) normafizc quickly after arJ.tibiotic treatment. 
Table 9. Ant ibiotic Management of PID (2010 CDC STD Guidslines) 
ORA( , 
--·------------------------·-····-·-·-··············--------------------.......... , ... _, _________ .......................... , .......... ___ i 
Ceftrixone 250 mg fM in a single dose OR. ccfoxitiil 2 g l.!Vl in a single dose and probenecid l. g oral.ly 
concun-eutly OR other third gen.eration parenteral cephalosporin (as ceftizoximc or ecfowximc) 
! 
i PLUS 
! 
l 
i 
i 
! 
i 
! 
doxy<:ydi.ne 100 mg omlly twice ~.l day for 14 days with or without metroni dazole 5DO mg orallyt\vice a day fer 
14 days 
! 
i PARENTERAL 
i 
i Re~imen A 
i ! Cefntetau2 g 1V every 12 hours OR cefoxitin 2 g rv every 6 hours PLUS doxycycline lOO mg orally or JV 
!. c-v{~ry 12 hott\'""S-
' Regimen ll 
! Clindamycin 900 mg IV every 8 hou:rs PLUS geatamici.nJoading dose N or TM (2 mgAg body \'.-eight) 
L. .. f?.~-~~.~:~-~-~Y . .:~.:~-~!~:~~~~~~~~-~:-~~:~~~.F- 5 mg/kg) every 8 hou:rs. Singte daily dosing (3-5 mg.tkg) can be substiL~Jted. 
::~·~·~ ~:~.1·:·1' ~:~ ~::·= .. : ~:: ~: . :==. ··: ·= :== .. :·=.:··= .·: ·= .. : • :~·· .: ~ ~ ~-: :.; :.: : ; :·~: :.: . 
I 
i 
l 
i 
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Differential d iagnosis inch1des other sour<:~s of right 
upper quadrant pathology, including cholecysti tis, 
pancreatitis, peptic n!ccr disease, hepatitis, 
pyelonephritis, pietldsy (with or without pneumonia), 
pulmonary embolism, pleurodynia, herpes zos ter and 
others. A rapid response to antibiotics is usually 
noted. Som~ individuals develop dl:ronic p<tin due to 
the adhesions, requir ing lysing of them for pain relief 
via laparoscopy. The correct diagnosis is based on a 
high index of suspicion in a sexually active femal e 
with right upper quadrant and gonococcal or 
cnlamydial infection which improves With antibiotics 
or which is confirmed via laparoscopy. Treat as per 
PID management guidelines (Tabie 9) via the 2010 
CDC STD treatment guidelin~s. 
Disseminated gonococcal infection 
Approximately 3% of women and l % of men with 
gonorrhea may develop scptlccn:da leading to DGI, 
with evidence ef dermatitis, arthritis or tenosynovitis, 
perihepatitis, meningitis, endocardi~is, and others; the 
most common fonn or DGT is the dermathis~arthritis 
syndrome. The most cmmnon form of dermatiti s is 
the vesicular pustule (4 mm<?. .S em) which rs 110ted 
within 2-t;. weeks of the urethral gonorrhea and is 
found as 2-9 lesions on the extensor ~mrface of the 
hands, dorsal surfac~;, oJthe arJldes and toes, and other 
areas. They appe<tr in crops at different times and 
probabJy reprcM>nt gonococcal embolization ar <m 
immttnobgi.caHy..mediated vasculitis, A pos1t1vc 
Gram stain an:d./or culture of the lesions may be noted:. 
T he pustuks develop i.nto pigmented lesions and dear 
without scarring in 1-2 months. Sonretimes purpuric 
macules on the palms or s<.Jles appear, as ·well as 
hemorrhagic bullae ia various areas, or a pekchlal 
rash over the hands, feet and ankles. The oral mucosa 
and scalp are usually spared, Secondary 
"lymphadenopathy does occur. 
A polyarthritis or monarthritis {tenosynovitis) has 
been described in the medical literature hut the pattern 
is variable. Many joints may be itwolved, including 
the kr:ee, ankle, wrist, the smaH j oints of the hands or 
feet stemoclavit ular joi11ts and oth~rs. The 
monarticular tyrc often affects the knee. The joint 
fluid is frequent1y opaque or slightly cloudy, has a 
poor mucin clot, i11creased pr(itcin and variable 
leukocytosis (10,000- 100,000 per cu mm), 
Gonococc-al dermatitis (see above) and elevated 
erythroGyte sedimentation rate (ESR) often occur. 
Tenosyr;Qvitis (dorsa .Qf hands or feet, wrists, AchiHes 
tendon and others) also occurs . The ESR rate falls 
with effective therapy (Ce.ftriaxone l gram IV dai.iy 
for 7 - l. 0 days). Jo int destruction occurs 'Nithom 
treatment. The urethral discharge may be minimal or 
absent when DGI symptoms appt~ar. Gvnococcal 
arthritis dermatitis syndrome is the main. type of DGl 
and is the main cause ofbacter ial ar'J.iritis. ~n sex111J.!y 
active teenagers and young adult~. Gonococcal 
osteomyelitis i s a rare co mplication of gonococcal 
arthritis. Rapid response to therapy is usually noted, 
but is slow if purulent synovial effusions are noted . 
Osteomyelitis requires a much iongcr treatment 
regimen. 
Treatment of DGI is usually with ceftdazonc (1 
Gram IM ot lV) ev·~ry 24 hoors until improvement 
dcvdops, often given for at least a week or more; 
alternative antibiotlc:.s ar~: cefota.xime ( 1 g ram IV 
every 8 hours) or cefliz.ox.ime ( l gmm l V every 8 
hours). Patients should also be treated for presumed C 
trachornatis. See the updated 201 2 STD guidcllnes 
fro m the US Centers for Disea~e Control and 
Prevention. 
Herpes simplex virus 
1nfcction with h~rpes simplex virus, type I, cause::; l 0-
20% of genital herpes while type n causes the 
majority. Type 1 can lead to herpes labialis, keratit is. 
eczema herpctlcum, an-d gingivostomatitis (l 0, ll ). 
There is an increase in HSV~ 1 anogenital herpes i.n 
yotmg womc11 and males having sex with males 
(MSM). Over 50 million i.•1dividua.rs in the 11T.! !1ed 
States (over 500 million worldwide) have genit~l 
HSV infection and the high est i:m.:idence is in the 
adoi~scent arid young adult age group. On!y one·· 
qlJarte r of those. with HSV · 2 intection .have know;; 
genital disease and most case~ are acquired from 
someone without known disease because of vital 
shedding in· both asymptomatic and S)"IlljJtomatic 
persons . L<itency and reactivation phenomena are 
classic witJ> HSV infections. 
A number of clinical presentatior:s for HSV 2 are 
noted, includi!lg a first clinical episode wh!.ch is. 
•::•:iJI••·•:•::::. 
. · ·:·:;:::~:::::: : : : 
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SP-Yually transmitted diseases 
pri.mary (with no prior HSV history and being sero-
negative f<.w testing), a non-primary first clinical 
episode (with a first recognized dinical episode and 
sero-positive for HSV··l and HSV.·2), rocurren1 
clinical episodes (with recognized, repeat dlnical 
episodes and sero .. positive for HSV -2) and 
asymptomatic prescntat;on (with no recognized 
cli.nical episode hut sero-positive for HSV-2). 
Clnssic c.linicall-TSV -2 iri the female presents as a 
c.crvkitis or vulvovagini1is that has a mucopu:ruknt 
discharge in asst)ciation ''tilth v~;lvat ulcerations. 
There can be otbpharyng!tis, utethritis, and proctitis. 
'fypk:ally there is itching or hyperesthesia followed 
by a number of small-group vesicles with 
erythematous bases that change or rupture into small 
shallow tender ulcers. These painful iesions can 
persist for 3 to l4 days before disappearing wit.hou.t 
scatTing. 
The lesions may arise on various locations of tbQ 
genit~tl.s ( vnlva, cervix, penis, periu;ethra) bl!t ca.."l 
spread to the vaginal, scrotum, urethra, CL"lUS, perianal 
areas, rectum, thighs. or buttocks, On~e or more deeper 
ulcers can be seen with primary dlscas~ in association 
with fever. headache, general malaise, anorexia, a:>ti 
inguinal lymphadenopathy. Uncomrmm complications 
with herpes genital infectivn include ~rythcma. 
mHW.P.>rme, meningitis, 
raciicu!ornye1itis (with acute 
hepa.tit failure. 
ascending myelitis, 
urinary retention), and 
Table 10 lists supportive laboratory data; cell 
culture :rod PCR (NAAT} are the recommended HSV 
tests f()r symplorrlatic patients . The Giemsa or \Vrigh.t 
~tain ca,n r~veal h<Illocn cells \vith intranudea.r bodies 
or multinuClear giant cells with electron microscopy. 
A Pap smear can reveal nmltinuclear giant cells; these 
can alsu b(~ seen .in varicella and herpes zo~ter. 'Those 
with geGltal., anaJ, or perianal ulcers should be 
scn~encd for syphilis and herpes; consider 
Haemophilus ducreyi if this is !Qcally prevalent. 
Laboratory testing for syphilis includes dark fic.Jd 
examination (at least once daily for 3 days) and 
syphilis serology (vida infra). Management of herpes 
labialis include~ oral or topical antiviral agents, 
sunscreen, zinc oxide crea1n, and topical anesthetic. 
agents. 
Table 11 li15\s recommended anti-viral treatmcm 
for HBV genital infection. Topical amiviral therapy 
shouid be avDided with .HSV gcnita1 infcctions-
f a.mciclovir and 1talacyclovir have greater oral 
bioavailabil.!ty and may offer the convenience of less 
frequent dosing cmnparcd to oral acydovit. Antiviral 
1reaH'nent does not eliminate latent virus. Rcseard) is 
ongoing with recombinant glyco-protein vaccines 
being developed . 
1'a!J1c 10. Supportive Labtrratory Dat11 fur G~nitlll 
He£·pe~ Simplex InJection 
:---~----------.. _ .. _ ........... _,, __________ , __ , ________________ ,_; 
C¢1! culture ! 
PoJymel'(:lSe Chain Rca.ct!on (PCR) :.esting (NAAT) \ 
HSV~spccific giycoprotciu G2 (HSV-2) ~~~. 
and G I (HSV- 1) 
Giem.sa stain or Wright stain (TzarJ< test) 1 
Pap smear ! 
Electron microscopy reveals viral herpetic i 
l ! "--'p'-'-a_r_ti_c_e_s_. -----------·---··-·--·--·-----------·- _i 
Trichomonas vagin.alis 
There are 5 million STD cases in the US due tv 
trichomoniasis; hal f arc asymptomatic in females and 
it is found in 5% ofmales att.eDding <:! STD dini!;; (15-
19). Prevalence in 18 to 26 y~~ar olds is -;2 ,8 % in 
females and 1.7% in Jnt!les. Three trichomon.as 
species are identified in humans: T bucca.lis in the 
mouth, T hominis in the gastrointestinal tract, and T 
vaginalis in the genital tract. Trichomonas vagi.na!is i.s 
a unicellular, t1age11ated protozoan which commonly 
causes a vaginitis and cervicitis with secondary 
vulvitis and urethritis. Trichomonas vaginalis is 
spread sexually including through c lose genital 
contact.. It h?..s been noted to survive for a fev,r hours in 
wet towels. The incubation period is 4 .. .30 d~ys , after 
which genital tnct infection occurs involving the 
vagina, cervix, bladder; urethra, Skene's (periurethral) 
and Bartholiu;s glands. The vagina is erythematous 
and contains a profus~~. greenish (or gray or yellow-
green), frothy ("htibbly"), malodurou.s discharge. Jt is 
intensely pruritic with a pH of 5.0 .. 5.5 or h!gh~)r, A 
mucopumlent or turbid vaginal discharge may be 
noted in 10 to l5% but this can also be seen with 
herpes simplex infection, chfarnydia infectivn and 
gonon'hea. 
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i 
[""ij·:·ii:~-t -episode (tontiu~~~-~;~~;--1(i'd_;~.-s if 1esions not fully resolved) 
i a. Acyciovi.r, 400 mg, oraUy, three times a d<>y fin 7 .. 1() days, or 
! b. Acyclovir, 200 mg, orally, five times a day for 7-10 days, or 
i 
i 
c. Valacyclovi.r, 1 gram, orally, two times a day for 7-10 days, or ~ 
i 
d. Famc[dovi.c, 250 mg, orally, ;:htee times a day for 7-10 days 
2. Recurrent epbod~s {shortens dundism uf lesions) 
a. Acydovir: 
-SOU rng, crally, two times a day, for 5 days 
-400 mg, orally, three times a day for 5 days 
-800 mg, orally, tl1ree times a day for 2 days 
OR 
b. Valacyclovir 
-1 gram, orally, nnce a day l{;r 5 days 
-5DO mg, orally, twice a day for 3 day$ 
OR 
c. F?mciclovlr 
-125 mg, orally, two times a day for 5 days or 
- ) 000 mg, orally, twice over one day or 
-50D mg orally; then 250 mg orally twice a day for 2 days 
3. Suppressive l\-'lanllgemeut {teduces freqmmcy of :rccu:rrcnces) 
a. Acyclovir, 400 mg, orally, two ti..'11es a day, or 
h. Famciclovir, 250 mg, oral!y, two times a day, or 
c. Va,lacyclnvi.r, 1 gram OR 500 mg, orally, once a day(valacydovir at 500 mg may be less effective for 
those~:: ~..?_?pi.sod_e:_.;/.::..y_e_a....:r):___ _ ~-·-··----·---------·----·--------·------·--·--·-·-·-·-·-·-·----·------------------~------------------·---------------
i'Strawbeny marks" (vaginocervical ecchymosis-2% 
of infections) and swollen vaginal papUlae are classic 
for trichomoniasis. There may be vaginal bleeding 
,~·ith genital trauma from C.:)itus or even touching the 
genital area with a cotion swab. Dysuria is frequent 
and severe cas(~S may present with 1ow abdom(;ml 
pain as well as excoriation of the vulva cr im;er 
thighs. Adniesccnts may be more prone to severe 
symptomatology than adults. Postpartum 
trichomoniasis has been noted with fever, leukorrhea 
and endometritis. A prolonged calTier state is po&slb.!e 
and may be associated \Vit:.1 menses ~ induced, acute 
cx~ccerbations, as well as chronic pelvic congestion, 
dysnwnorrhea and menorYhagia. 
The diflcn:ntial diagno~is includes vu1\ravaginitis 
due toN. gonorrhoeae, Candida albkans, or bacterial 
vaginos!s. The pres(..>t1Ce of the leukorrhea or cervical 
infection is not enough for diagnosis. For example, 
what appeurs as an "inflamed" cervix may tx~ a benign 
cervical erosion in \:vhich the endocervical columnar 
epithelium spreati5 out oftbe cervical canill, forming a 
border around the external os. 
The saline drop/wet mount (sensitivity of 60-
70%), Papanicolaou smear and/nr cuiturc (most 
sens;tive) can aid with the diagnosis. A saline 
prepamtion reveals numerous pcar~shc.ped motile 
microbes which are unicclluls.r flagell;~ted organisms 
twice the size nf a white blood ceiL These microbes 
niay not be seen in chronic ca..1Tiers if urine is the 
sarnple study or if the patient used a chemical douche 
prior to the exam. The 1u.brka.r:t used on the spe(:ulmn 
can ah>o hinder this test result. These organisms can 
also be noted in urine samples or on Papanicol<Jou 
smears. However, the Pap smear can result in false 
negarlve .. as well as false positive results. Cultures 
are possible in some laboratories; these are helpflil in 
suspicious cases wlth mu!tlple negative saline 
preparations. 1'-DA-de<>red tests include OSOM 
Trichomonas Rapid Test (color 
immunochromamgraphk fdipstkk! technology) ar:uJ 
Affirm VP III; the latter is a nucleic acid p-::ohe test 
t~'}r T. vaginalis, C. albkans, at1d G. vagina1is. 
Treatment is with nitroimidazoles such as 
metronidazole and tinic!a10Ie. Metronidazole car,. be 
t 
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given as. a single two gram dose or tinidazole is given 
at 2. grams orally in one dose; ~m altemati ve regimen 
for mettonid~tzo1e is a 7 -day oral course (500 mg 
twke a <lay). Tho<>c who drink alcohol need to avoid 
this substance during trcatm.cnt and for up to 24 hours 
after taking metronidazole and 72 hours after tak~ng 
tinidazole. Treatment '.Vith metronidazole gel should 
be. avvide_d~ 
FoHmv-up ts not necessary if the dinical 
symptoms rapidly resolve while the uncommon 
resistant infection (not rcinfecticm) can b(~ tre:1ted with 
thG 7 day course (500 mg BID) of metrrmidazok; if 
the infection is still mH resolved, 2 grams (single 
dose) of metronidazole is given once a day for 3-5 
days. {2010 STD Guidelines, CDC). Vaginal infcctiort 
is associated \vith adverse pregnancy outcomes and 
pn~gnant patients with T. vaginalis vaginitis can be 
treated with the single lwo gram dose regimen of 
rnetrorddazole. Those v:ith an immediate-type anergy 
to metronidazole can be treated with desensitization. 
Resistnnce to nitroimidazoies remains limited. 
Metronidazole does have numerous sidr;: effects 
including monilial vaginitis, confusion, ataxia, 
nat~sea, anorexia, headache, dizziness, transient 
neutropenia, metallic taste; dermatitis, diy mucosal 
sttrfaces, urine discoloration. and periphetai 
neu rapath y. 
Flushing and nausea with emesis occurs when 
metronidazole is combined \Vith alcohol due to a 
disulfiram effect The single 2-gram dose may redu~~c 
many of the side effects for the disulfiram effect. 
Tinidazo1e side effects arc similar to metronidazdc 
but also tnclude post-marketing reports of severe 
dermatological reactions including erythema 
muhiforme and Stevens-Johnson syr:.dwme. As noted, 
avoid alcohol f()r 72 lwurs after taking tinidamle. 
Bacterial vaginas is (B V) 
In this scxualiy-assndated (or enhanced) infection, 
there is an iacreased growth of anaerobic bacteria in 
Lhe vagina, including gardncrcHa vaginalls, 
mobi.luncus species, bacteroides species, p:revotdla 
sp, ureaplasma, and others; Mycophtsrnas hcminis is 
also noted while lactobaciHi are reduced . BV induces 
ll. vag!nitis characterized by a non-itchy, gray-white, 
frothy, tnillodol'ous vaginaJ discharge with a pH 
usuAly less than 4.5; specific cervical or biadclcr 
infection is not found. HV can be noted in as many a<s 
50% of sexual ass<iUlt victims evaluated >Vithin 72 
hours of the assault (23). Transient gardnereila 
vagina!is bacteremia has alsn been seen, usua11y 
associated v<iith delivery or abortion. ln ~exual1y 
activ<~ individuals the presence cf BV also increases 
the risks tor gonococcal, trichomonaL and chiamydi<~l 
genital infcdion in addition to HrV and H.SV-2. The 
frequency of coital behavior and numbers i.)l scxua1 
partners may be factors for BV acquisition in some 
females. 
Clinically, the vaginal discharge, vaginal pH, 
Whiff test, and wet mount fbi clue cell~ are used f~!r 
the diagnosis of BV Gram stains of vaginal fluid, 
typically only obtained in research studies, reveal 
decreased Lactobacilli and increased anaerobic 
bacteria. A saline preparation or Gram stain of the 
leukorrhea. identifies due cells -·-· cp!thclia.i cells 
covered ("studded'') with many Gram-negative bacilli; 
a positive sample is when 20% O( more of the 
epithelial cells are covered wit:.'l bacteria. 
'the sensitivity of the wet mount test is 70-90% 
(versus 75-80% for the low pH) and spcciGchy is 95·-
toO% (versus 60-70% for the low pH test). A less-
proven test is producing an a.rnine-Jike odor when a 
small amount of this discharge is mixed with l 0% 
potassium hydroxide (KOH) solution (vlhiff test). 
There 1s also a DNA probe to detect high 
c:onccntmtions of G vaginal is; the Atlirm VP HI test, 
as noted earlier, can det(~Ct G vaginalis. 
Table 12 lists the 2 010 CDC recommended 
treatment options fvr symptomatic BV. fi)]low-up bf 
non-pregnan_t patients with BV w1w resolve with 
recommended treatment ls usua.Hy not necessary. 
Thete ate n:o recommendations to treat the male 
partner of the female '"'ith BV and it remains debated 
whether or not to treat asymptomatic BV in pregnant 
women without a previous history of preterm 
delivery, since it does not prevent pretcrm labor and 
delivery. 
Human papiilomavirus (HPV) 
Human PapWornavi rus (HPV) is a double-stranded 
DNA virus t..'lat ac:coU:.'1ts for 20 tnUlion or more STDs 
in the United States (6-9). 
. :. ~; 
: :' :~ 
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T~ble 12. M;magetneutof Dacterial Vaginosis (CDC STO Guidelim:~g, :20Hl) 
i J~rer~~:red"-("N-or;~:p;:;g:n;~nt, ntlT!-lac1atir.g)------------------------------------·-~----~-----------------------------------------------
i Metronidazole (500 mg Bm orally for 7 days) OR 
i Cli.udamycin cream (2%) (one full applicator [5 grams] intrava.ginaUy before bedtime for 7 ch.ys) OR 
l Metronidazole gel (0.75%) --one full applicator (5 grams) irltravaginaHy, once a day for 5 days. 
j Al.t.enrative (Non-pregnant, non-lactating) 
l Tinidazole (2 grams oraHy om:c daily for 2 days OB, 
Tinida.zn!c (1 gram. orally once dally for 5 days) .Q.R 
Clindamycin -· 300 rng 'wally twkc a day for seven days O.R 
Chndamycin ovules (100 mg intravaginally once at bedti.i1le for 3 days) 
Preferred (Pregnant) 
Mettonidazole (500 rng oraHy, twice a day, for 7 day~) OR 
Metronidazole (250 :mg orally, three times a day, fbr 7 days) OR 
L.._ __ C_J_in_d~~~~0-- 300 mg orally BfD for .seven_9_ays 
HPV subtypes arc idcntifit:d with an immunobbt 
typing systeni; more than l 00 typ<;s are now 
recognized, incbding these ofkn associated with 
clinicHl symptomatology with approximately 40 that 
iritcd the genitals and ~lt !east 14 that are oncogenic. 
Types 6 and 11 lead to genital condylomas and type 
16 is the most common cause of anogenit.a.l cancer. 
Other oncogenic types inciude 18, 31,33,35,39, 45, 
51, 52, 58, 59, 68, 73, and 82. There is an incubation 
pedod of a few weeks to several montl-H;; it infe.cts 
basal epithelial ceHs. Hi~ sexually transmitted and is 
often associated with other infections (C albicans) 
and STDs (q.s trichommliasis and gonococcal 
cervicitis), 
HPV is noted (n 3-8% of unsc1ected young 
female patl.cnt-;; 25--50% of patients seen in a sexually 
tran<:mittcd disease clinic -..vcrc noted to have HPV 
using colposcopy. As many as 70% of these particular 
patient's sex partners displayed warts or had them 
before. Biologic risk factors f()r acquiring HPV 
include the presence of cervical cctopy, micro trauma. 
and immature immune response capacity. Most HPV 
infections are acquired early in the sexual lite of the 
patient and adolescents may be more vuherahle to 
this infection thrm ad1ilts, from a biological vie\vpoint 
Viral protein transcription leads to various HPV 
manifestations: warts. dysplasia, and cancer. The 
riPV \V<Lrt lesion may involve any part of the genitals 
(including the vagina, urethra, bladder, or anal canal) 
and the infection can be very extensive. They seem to 
worsen in individuals with vaginal di5charge, poor 
hygiene, heavy perspiration, aod pregnancy. Lesions 
resistant to treatment are reported in some individuals 
_______________________ , ______ ......J 
with insulin-dependent diabetes mdlitus and with 
immunosuppressive disorders, 
Most HPV infections in humans arc 
<isymptomatic and are only dctecLcd by colposcopy or 
pap (Papanicolaou) smear testing. Thus, the 
prevention of liPV in.f{~Ctions w[th the HPV vaccines 
is recommended for females and males from ages 9 to 
26 year::; of ag{~ "in contrast" to treatbg the ;va.ti.S or 
cancer that develop after the infection. The bivalent 
vaccine (Ccrvarix) offers protection against HPV 
types 16 and 18 whik th~ qu.adriva.lent vaccine 
(Garda.sii) offers protection against HPV type~> 6, I I, 
16, and 18. The quadrivalcnt va.ccine provides 
protection against the two most common HPV strains 
that cause genital warts. The vaccine is a three dGse 
seties and co.n1mon side eftects include fever, 
injection site reactions, arthralg.ias, and f<itiguc. 
Syncope sometimes associated with tonic--donk 
movements or other seizure-like activity has been 
rcpvrted and observation of the patient for fifteen 
minutes after administration is recommended. 
The Bethesda system LSlt (low-grade squamous 
intraepithelial lesions (LSlL) corresponds to the 
WHO ClN ((·.ervicaJ intracpithdial neoplasia) l 
classitkatkJD versus HSl.L (High-grade squamous 
intra~pithe)i;).l h:f>im:) re!1ect~ CTN II a:nd 111 HPV is 
necessary f(y the development, maintenance, and 
progression of ClN; HPV is linked to cervical and 
vulvar neoplasia as ·well :~s anal cancer, penile car.cer, 
and oropharyngeal cancer. Though the timing of 
starting Pap sn1ears is controversial, rhe Arnerkan 
College of Obstetricians and Gynecologists 
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recoramends initial Pap smear scrccnh1g at age 21 
regardless of t.he sexual history. 
The di ffere·nt!al diagnosis l}f HPV \varts. indudes 
mol!usn.lm coniagiosum, condyloma lata (syphilis), 
s.kin tags (peri--anal), urethral prolapse, and. pc::trly 
penile papules. The presence of squarnous papillomas 
in moist mucocutaneous areas of the external gcnitaha 
and perianal regions is usuaHy sufficient for its 
diagnosis. Biopsy is confirmatory <md mandatory if 
lesions are rc~.lstaJ'1t to podophyllin therapy. Voiding 
cystomethrcgraphy will demonstrate if intra1..iretlmd 
spread has occurred. Co lposcopy is used by some 
clinicians but there ar~ probJ~ms with access and cost 
Cytology (Pap smear) is the most practical diagnosl.ic 
toot but has low sensitivity and specificity. Molecular 
diagnostic modalities include in situ hybrk!ization, 
dot-blot (commercially available ViraPa,p/Vira Type), 
Southern. bl.ot and PCR. The PCR (polymerase chain 
reaction) is the most sensitive test for HPV. H)•hrid 
Capture is FDA ~approved to evaluate i 4 high risk or 
cancer .. assoclated HPV types. 
Table 13 llsts the therapy options for warts. 
Therapy of concomitant STDs and using 10-25% 
tincture of podophyllin (podophyllum resin. in tincture 
of benzoin) on the ksions may be helpful, especially 
if the ateas are less than 2 em in diameter. White 
pctro.laturn jelly may be then added and this mixture 
of podophyllin and white pcttolatmn jelly is 
thoroughly washed off ln 2-4 hours. There ate other 
techniques for using podophyllin but tht~se all stress 
that normal tissue must be protected from. the caustic 
podophyllin that induces pain. \Veekly applications 
may be necessary and seems to be most effective with 
moist, fleshy, sessile genital warts. 
The rt)le of more f.requ~nt appli~a,tian h urid\:r 
study and the goal of treatment is to rernove the 
symptomatic wart. Regrcssioh is .noted in 79% within 
2 years and there is no evidence that treatment of 
overt warts afi:ects the development of cervical 
cancer. Persistent infections are associated 
:;moking, other STDs, multiple partners 
immunosuppression states. 
with 
and 
Podophyllin is not used for cervical warts or for 
pregnant patients. If there is not regression after G:>LU' 
weekly trials, other metJ1ods are used. U"nfottl!nately, 
there is no treatment proven to er;tdicate this virus and 
no specific regimen to ahvays remove Ute warts and 
ptevent recurrences. In ?.dditioh, no ()ne treatt!lellt 
su.ites all patients ~nd th~rapy should be 
individualized. 
The use of topical chemotherapeutic agents (as 
80-90'% trichloroacetic acid [OK for pregnancy and 
m~1cosa] or 5--fluoro.uracil) has been used as 
alternatives to topical podophyllin t reatment 
Podofilox (U:5%) i;; availabl~ t(~r h~m1e use; others 
inciude Irniq11irnod 5% cream and Sinecatechins 15% 
ointment None of the at-home treatments have beea 
adequately assessed in pregnancy. 
Table 13. Trea.tme11t Options for Exlern:d Gcnitll.l Warts (2010 CDC STD Gtli.ddi..ucs} 
---·-·-·---- ----------------------------·-·-·-·-·--------·-·----: 
A. TOPICAL APPLICATION ! 
Prttient··applied.: 
Podof11ox 0..5% solution.or gel 
Imiqui.mod 5% cream 
Sinecatechins 15% ou1tment 
Cryotherapy w!th liquid nit.:rogen or cryoprobe 
Podophyllin resin lD%-25% (in compound tin{;nm: of benzoin) 
Trichloracetic acid {TCA) or Bi.chloroacetic acid (.BCA) S0%-90% 
B.OTIIER 
i 
i 
l 
l 
l 
; 
; 
1 
; 
; 
Surgi~:a! removal ofwar!s ; 
; 
lntr<\let;ional interferon injectior j 
Laser surgery 1 
Topical cidofovi.r i 
'----~--------------·····""""""" .......... ... ... . ...... ............. "'""'"'·······--·· .. ························--·--·--·--··-· .............................. ... ......... _. •..• _.--< 
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Methods which have been recornmcnded. as 
alternativeS" to podophyllin therapy include curettage, 
e!ectrocautenz:aticn, loop ekctrcsmgic~1 exclSlon 
procedure (l.EEP), alfa i11terferon, surgical excision; 
and cryotherapy (with liquid nitrogen or solid carbon 
dioxide). immunotherapy with a11 4utogenous v accine 
(prepared from excised warts) has been attempted but 
i.s without proven success. Laser treatment has also 
been used with succe!>s. Careful tollow-up of these 
patients is important, due to the Hn:k of this virus to 
cervicn1 cancer and other cancers. 
Vulvovaginitis 
Pt;berty exerts a profound estrogen effect on the 
female genital ttact that produces a thicket, longer 
vagina. with a:n adult effect on tb9 vaginal cell count: 
approximately 60% superficial cells, 3l ~;;; 
in termediate and 9% parabasaL 
The pH: is in the acidic range (5.0 to 5.5) due to 
lactic acid production partially f.rom the presence of 
Lactobacilli (Table 14). One rcsul.t of th is thickened, 
acidic vaginal milieu is increased protection against 
infection. Vdvovaginitis tends to be due to specitic 
causes (Table 15), many of which are covered earlier 
in this chapter. The prese.nce of cett ain identified 
pathogens (i.e., neisseria gommhoeac, trichomonas 
vagina lis, cundida alblcans, gardnerella vagim~Iis) 
docs not always mean a.symptomatic ir.fection exists; 
sometimes a 'triggering mechanism (<)fien not known} 
must occur before •wert symptomatology occurs. 
Table 14. No:rma! Flora of the Vagina after Puberty 
Dodt."f.leih's lactobaci!!i. 
Bnte.::ob;:1ctcriac,~ae 
Bacteroides .fi"agilis 
Neisseria sicca 
Streptococci (i.ncluding gtoup B) 
Stapbylcicocci 
Diphtheroids 
Ccmdida .albicans 
Other yeasts 
Other anaerobic bacteria 
Other microbes 
·-·-··-----.. --·-··] 
' j 
! 
i 
! 
i 
i 
i 
! 
I 
i 
i 
I ............................ ... .......................................... ... _. _____ __, 
Physiologic leukvrrhea 
Physiologic leukorrhea re fers to a normal increase in 
vaginal discharge (leukorrhea) due to a puberty-
stimulated increase h estrogen prodtfction; it can also 
be noted in the flr~t few days or weeks after birth in 
the female newborn due to maternal estrogen .. in early 
pnberty the vaginal 4ischatg¢ is from. muct:S sectetion 
of the cervical coiU.ml1<U' epithelium, vaginal \VaU 
fluid trar.sudatior;, and multiple gla11d stimulatio11 
(i.e., Bartholin' s, st:baceous, and sweat). Classically it 
initiates several weeks or months prior to menarche 
aod is variabl.~ in amount until regular menstt'1.1ation is 
established. The leukon·hea rs typically dear, sticky, 
and non-irritating and may increase during pregnancy 
Pr even during se>wal ar<.rv.!iai. 
Table 15. Cause~ nfVuivmraginiH~ 
•••••••• •• • •~~ -., ....,. , __ .....,,~H••••••••••••••• •••• •••••••...,o ..., _____ ...,,, .,,,,,, ,,, , ,,, ,,,,,,,,.,,....,,....,~---~•-••••••••••••••••••••-•••••••••uooo.oooooooooooo o•••••••••••••••• ._,. •-• 
1. Leukorrhea nnd/or vaginitis 
a. Physiologic leukorrhea 
b. Candida alhicans vaginitiS. 
c. Bacteria[ vaginos!s 
._ ........ 4: .. !.'~t.C:.?!!~~'J!!.~~q~ vagin~!!.·~-\~.lli!.Jj_~~--· --· · 
2. Cerv(citis dtte to 
a. Chlamydia trachomatis 
b. Neisseria gonon·hoeae 
·-------......................... _____ .. ,_ .............. -------.. -----·-··-····-
c. flerves sim lex ~~~in1s 
!----,--c-::"---...._~--.:. ........ _,, _____ .. _.,, .. _,,_,,, .... _ ..... ____________ , ....... ______________ ,___ ,.......................... .. 
3. Miscella,'1em:s 
a. Allergic vulvcvagillitis 
b , Foreign body vaginitis. 
c. Vulvar ulcerations (herpes, syphilis, ch:mcroic, lymphogranuloma venereum gn:nt:!oma. ingui~~ale , amebiasis, 
Behcet's syndrome, others) 
d. Vulvitis (scabil"s,. molluscum contagiosum , pecHc~iiosis, warts [HPV], tinea, psoriasis, furwJ]cuJosi~, pruritu:; 
.......... Y~.}:!Lvac, othSI_~L .. _ .................... _ .. ___ .. _ ............................... ______ _ ------·-.. -.. -............. ·-----' 
~t~l~S:~~{·; 
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Sexually t.nmsmitfed dLww.ses 
A saline preparation of the vaginal fluid rev{~al.s 
1wm1al vaginal cytology without leukocytes ot 
pathogenic bacteria. Cultures of the 'iaginal t1uid arc 
not necessary but, if obtaip.cd, arc negat ive. The 
young adolescent female may be concerned that it is 
due to genital injury or a sexually transmitted disease. 
Nylon undergarments absorb the t1 u1d poorly in 
conti'ast to the excellent absorptive powers of cotton 
illldergatr!lenis. Good perineal hygiene is 
recommended and norrnai baths and medication 
shouid be avoided; inadvertent nse of rnedication car) 
lead to such sequelae as dermatitis medicamentosa. 
Ccmdid(t alhica.ns 
Vu lvovaginal candidlasis (VVC) is a common cause 
cf vulvovaginitis no! ci<'.ssi:fi:cd a<; a sexully 
tn;nsmitted ciisease and dne to Candida albicans in 80-
90%, Torulopsis glabrata in 10-15% and C. 
parapsUosis in 1-2%. Table 16 lists various 
precipitating factors in the development of recurrent 
ar chronic VVC. VVC typically p:-escnL'> with v;:tgino-
vu!var erythema, intense pruritis, and a whitish, 
cottage checse .. Jike v:1gina! dis chargt:: 'v\'ith a pH of3.8 
to 5.0 (typically <4.5). Itchiness with erythema and 
decrca~ed !eu .. 'wrrhea tnay occur if the infection is 
pre~ipitated hy antibiot,ics; more leukorrhea occurs if 
VVC deveiops dttring pregnancy. Increase in th::. 
discharge may occur before un.d after menstruation 
but may decrease during menstruation. 
Other symptoms tl1at may occur include urinary 
frequency, dysuria, and dyspareunia. There may also 
be fissuring, lichenification, a11d secondary bacterial 
infection over the perineal areas or legs (inctuding the 
ihighs). Skene's glands and endocervical glands :may 
also be infected. The prcsem:e of thkkcned, bronzed, 
or dul.l red skin over the labia or groin suggests 
chronic infection. .Oerma1op.hytids (Mor. j1 ids) can 
develop as very pruritic but sterile lesion:> at the sides 
ofthe fingers and hanck Laboratory testing reveals a. 
vagitmi secretion with a pH under 5.0 while a 10% 
KOH preparation shows hyphae (mycelia), pseudo-
hyphae (non-detached buds), yeast (1Jvai cells), and 
possibly white blood ceHs; the exruu js negative f(:)r 
clue cells ~nd trichornonads. Culture can ;:;!so be 
accomplished. The only FDA-approved oral 
medication ls fl t;conaz,o.le ·Jmt is given as 150 mg 
tablet (Table J 7). A number of azole agents 
available as topical agents, as noted in Table 17 
are. oil-based and thus, may ·weaken. latex . 
and diaphragm~. Topical. azolcs aj'e consid(:n~d rn6re 
eftective tbau nystatin and arc recommended for use 
during pregnancy; short courses ( l -3 days) are as 
eft(lctive as longer courses. C. albicans. cru:t be tound 
in as rnany as 20% of females without VVC 
symptoms and <H'lti-fungal t reatment is usually net 
i:ndkated ill this situation. Treatment of sexual 
p~tttners of fcrna.les with symptomatic VVC is not 
recommended unless she has re.current or chronic 
disease. A lltinority of male sex partners of fbnules 
with v-'/C may develop balan.itls th&t usi~aHy resolves 
with topical anti fungal agents; other potential causes 
of balanitis include herpes simplex virus and primary 
syph ilis. 
Femal~s with recurrent VVC due to C albicans 
may be managed wi1h a s ho1i cvilrs~ of fluconizoie 
(100 to 200 rng every 3 days fm 3 doses) or oue to 
two we~ks of topkai agents ; longer '"rnaintcnanec'' 
anti fungal treatment may be considered (20 lO CDC 
STD management guidelines). Most have 
nncomplicated VVC. Complicated VVC is not wcl1-
underst0od and involves those females with recurrent 
VVC (4 or more episodes per year .. ···found in <5%), 
severe \lVC, non-a1bicaus candidiasis, or those with 
uncontrolled diabetes mellitus or immunosuppression 
states. Females with nou-aJbicans VVC can be treated 
with nor).-fluconazole azcle drugs (txal or topical) for 
7 to l4 days, Numerous drug interactions exist with 
oral azoic agents due to cytochrome .P450 enzy me 
metabollsm and i.nhibition. A patient's medication 
regimen should be revie\Ned fot drug intcmctim.'ls 
before initiating an oral azole medication. If further 
infection occurs, use boric acid {600 mg) in a sciatiJl 
capsule intravagi.nally, once a day, for J4 days(!). 
Miscellaneous STDs 
Many other STDs are noted in youth . Group A 
streptococci can cause a vaginitis in prepube1tal 
female ::; after t ransmission by sexual contact or 
autoinoculation from Lhe pharynx; managcmet:t is 
with 10 days of penicill in. 
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Tab(f.16. Predpitllting Fa<-tors for Chronic ur Re~~-:nent VVC' 
Rednction of host defense mec]l(!,"lisrn 
Chronic illness 
Steroids 
Aging 
Severe iron deficiency anemia 
Imtutme disorders 
Chrvnic Candida exposure 
Infected se.:( prutner 
Contami;1ated soap~ 
Intestinal reservoir 
In<:re<lse in heat qr moisture 
Obesity 
Tight nylon undergarments 
Lmver the p.H 
Pregnancy 
Oral comrayeptives 
Diabetes Mellitus L---- .. ,_, ........................................ - ..................... .. ----------------........................... . 
Tahle 17. Mznage.m~nt of Vulvovaginal Omdidiasis (VVC) 
, .. T .. oj~}~;g·~~i~".fi~couazoi"~* ( I so mg oraJtab) i~-a singJc ci~.~~-----........................ _ .................................. . 
l 2. ClotrL>nazole: -cream {1%) (5 grams) iniravagina!Jy for 7-14 day;; or -cream (2%) (5 gmms) intravaginally for 3 days 
3. Mjconazoie nitrate: 
.. vaginal cream (2%) once daily (5 grams) for seven days 
-vaginal cream ( 4%) once daily (5 grams) fi)t three days 
~200 mg vaginal suppository, one suppositoryfortbrec days 
-100 mg vaginal suppo:ritory, one suppositmy fiJr seven days 
I 
[ 
i 
I 
i 
4. 2% butaconazole nitrate (Femstat) cream -- 5 grams given [ntravaginaHy for three d.ays. 
i,',,, ~ l ,200 mg vagir:al.~uppository .. ---us.e once ~ 
i 
i 
i 
i 
! 
s_ Otht.m: include tioconazole and terconazole* and (\S topical agents. 
~pres<:ription only __ .............................................. -.... - ............... --~-----
·rablc 18 cutiines treatment for pediculosis pubis (due 
to Pthirus pubis) and scabie.s (due to Sarcoptes 
s~abiei). Increasing resistance w ith perrnetbrin and 
pyrethrins may require use of malathione if treatment 
failu.re occurs for pcciiudm.is pubis. 
Due to t.t1e neurologka.! toxicities associated with 
llndane, permethrin and i vermectin are considered. 
first line trt:atments for sc;>bics. LindanQ and 
ivcnnectin should not be used du;-ing pregnancy. 
Pi:tlwOrrns (Enterobius vermiculatis) may (,;.ause- rcctai 
and vaginal irritation as well as pruritus. The won:r:s 
may be found in the perianal area at night or 
identified with the cellophane tape test. Treat \-vith 
pyrantef pamoa·te (Mwprescription: l t mg/kg with 
'maximum of l gram orally; r~peat in 2 weeks) OR 
with prescription medications: mebcndazo.k (i 00 mg 
tablet once and ma.y need to repeat in 2 weeks) or 
albendazole VlOO mg tablet and repeat irt 2 weeks; 
unlabeled indication). All famity members in dose 
contact with the patient should also be trcatt~d . 
Lymphog ranul,oma venereum (LGV) is an STD due to 
infection with Chlamydia tTachcmat1s (~erotypes L1 , 
L2, and LJ ) with an incubat ion period of3 to 30 days; 
it callses inguinal 1ymphadenfJpathy (buboes) that is 
painful as. wel! as genital ulcers and severe ukerative 
proctitls (proctocoliti~) . The pl'imary lesion may be a 
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smal1 red erosion (oilen missed) with fever, malaise, 
myalgias, and arthralg!::::.s. Unilateral lymph nodes 
above and below the inguinal ligainent are called the 
"groove" sign. fTntreate4 LGV can lead to bo\vel 
obstruction, bowel perfora.tion, rectal strictures, an.d 
even death. Molecular testing is availabk to establish 
a diagnosis of LGV vvhill~ t.re;~trnen.t irwolves 
doxycycline (1 00 mg orally, twice dally, t~1!' XI day:~); 
an alternative plan is ~rythromycin base (500 m.g 
mally QrD for 21 days). Erythromycin should be used 
Juring pregnancy a.nd in lactating femaJes. 
Chancroid. (due to haemaphilus ducreyi) has an 
incubation period of 3 to 14 days and presents with a 
small, painthl, erythematous papule that classically 
erodes into a r~.gged ulcer with undetermined edges; 
there is usuall~' painild, often uniiRteral, inguinal 
lymphadenopathy tlut may be Sllpporative, 
Laboratory data may include culture (often difficult to 
obtain) and PCR testing. Management Is with 
ceftdaxone (250 mg TM), dprotloxac in (500 mg HID 
f~':lr 3 day.s) or azithromycin (1 gra;.-n orally); an 
ahernativc plan is erythromycin base (500 mg TID for 
7 days). Fluoroquinoionc.s should be avoided during 
pregnancy and in lactating females. 
A. Pediculosis pubis 
Granulo_ma inguirtale {donovanosis) is du.e to 
hf'ection with K1cbsleHa granulomatls (formerly 
called Calymmatobacterium gnmu1omatis) that has 
incubation period of 2 to 1 0 weeks and presents with 
an erythem;:;.tous nodule or papu1e that is usuaHy non-
pairtf'lll but then utcerates to form friable, beefy-red 
granulation tissue; tisslle b iopsy can note Donovuan 
bodies. Inguinal lymphadenopathy is not nsua11y 
noted b'1t perilymphatic g.ran.nlomas ("pseudobubos") 
may mimic enlarged lymph nodes. lt is treated with 
doxycycline (J 00 mg oraiiy, twice daily, for at least 3 
\-Veeks) OR I 60 mg of trimethop1im with 800 mg of 
sttlfm:nethnxazok ---nne tablet orally, twice daily, for 
3 weeks). Alternative trec.tments include ciprof1oxacin 
(750 mg orally, twice a day, fat 3 weeks), 
erythromycin base (500 mg, orally, four times a day 
for 3 weeks), or 3.zithrmnycin (l gram orally, per 
week, for 3 weeks). ln pregnancy, erythromycin is 
pteferted and inclusivn of an intravenous 
aminog,lycoside shm:dd be considered. Treatment 
should continue until all lesions have completely 
bea1ed and relapses can occur despite appropriate 
treatment. 
Permethri.n (t% cream rinse--·--app'ty to affected areas; 1.-vash off in 10 minutes) OR 
Pyrethrins (with piperonyl butoxide··--·appiy to affected areas; wash off inlO mim;t:es) 
.-~ltemative: 
Ivlalathione (0.5% lotion applied for 8 to l2 hours; wash off) OR 
Ivermectin (250 meg/kg oraUy; rep"at in 2 weeks) 
H. Scabies 
Pennetltrin* (5% ~rcarn~apply ti·cm neck down; wash off in 8 to 14 hours) OR. 
1 !vennectin* (200 meg/kg oraily; n:pe<J.'- ill 2 weeks) 
! A lternativc ! ·- -~~-! Lindane* (1 %): i oz (30 gr;;m) of cream applied in a l.hin layer to ail arqas from the neck down, wash off 
I thoroughly ai:ler !\ hours; d~l not apply directly after bathing. 
l .... ~~J)-~~EE.~P..t)_i:~L?.'ll:i ......... _ ..................................................................... -----~-·· ........... - ...................... ________ .........J 
Syphilis Is an STD of antiquity due to Treponem<:1. 
paHidurn with an incubation period of 9 to 90 days 
(average of3 weeks) (25). This pathogenic spirochete 
gains access via mucos~.i abrasions during sexual 
activity "vith the indlJction of a Iocal immune response 
and secondary hematogenous spread. P rimary syphilis 
presents with the classic chancre that is a well-
defined, painless, etythemataus ulcer with a firm 
(rubbery) base; there JS usually inguinal 
lymphadenopathy that can be bilatetai or unilateral, 
<l.nd typically nontcndcr as \Vell as non-suppurative. 
Diagnosis is \Vith darktield microscop~.r to 
identify the trcpm1cmcs and serology (non-treponr~mal 
tests: R.FI\., VDRL). The sensitivity of R.PR or VDRL 
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is r..il!her in secondary syphilis versus primary or 
la1cnt syphilis; also, RPR and VDRJ.. arc associated 
with ii1lse ppsitivc results and false negative results 
(nrozone react! on). Direct fluorescent antibody testing 
(i>F/bTP) of smears can also be used i.f available. 
ireponemal tests can be used: fluorescent treponema\ 
antibody absorption (fTA-ABS) .and 
tn icroh~magglutination assay (MHA-TP) that remain 
positive for a lifetime il1 most (despite treatmet:!?-
Screen those \Vit:h a history of expo~ure to syplul!S 
with an RPR or VDRL and if positive, do a 
treponema! t:~st(i . e . ~ I\1HA-TP or FTA·ABS). 
The chancre lasts 2 to 6 weeks and wiLl resolve 
even without treatment. Secondary sy philis appears 6 
weeks to 6 inonths after disappearance of the chanc:re 
and ca.'1 present with a wide V(lriety of constitutional 
syrnptoma.tology in Its role as the "Great Imitator": 
malaise, fever, generaJized lymphadenopathy, 
heoatospenomegaly, . rhinitis. sore throat, alopecia 
('';,oth--eaten:", patchy), polymorphic rash (with or 
without involvement of the palms and soles), 
headache, arthralgias, anogcntial condy'l omata lata, 
and many others . 
The .rash of syphilis may begin as a .red, l~ac_ular 
eruption first on the extr~ruities and trunk; l{\Slon:s 
may become elevated with .a copper-red hue and 
· l 0 1 I' k ' · n involve the palms as well as so es .. { a.que- 1 e ;csJo s 
may be seen that mimic psoriasis while the 
appearance of rings CaJl. mi.rnic ~"inea c-orporis. 
Condyloma iata appear as skin-colored or gray, 
macerated papules in the perianal or genital an~a; 
there can also be mucous patches that present a.~ oval, 
gray erosions on tiw genital areas or in the oral cavi:Y· 
Secondary syphilis can la.<;t 2 or more weeks and also 
resolves wlthout treatment. Later stages can occur that 
&.i'(~ rarely seen in adolescents_. induding early latent 
twithln one year of inJec:tion), late latent ((:an pt~rsl.st 
for n1any years v.·ithout symptoms). latent syphilis of 
unkn(W·itl duration; and tertiary (neurologic, cardiac, 
gurnmatous lesions). . 
t'rimarv. se»ondary, a..•Ki early latent stage-s ot 
syphiJis ar~ treated w ith Benzathir1c Pe nicillin G {2.4 
million u;1ils lM) in one dose; late latent, latent 
syphilis of unknown duration, and tertiary syphilis 
(not 11eurosyphilis) arc treated with Benzathine 
Penicillin G (2.4 million units fM) weekly for three 
weeks. Neurosyphilis ~>hould be treated wit..i:J 
intravenous penicillin G (18-24 minion units per day) 
for 10-14 days. A patient with syphilis who is allergic 
to peniciilin is desensitized and treated with 
penici!lin. Altematlve treatrnent in non-~pr~gnant 
individuals is tetracycline {500 rng, orally, four times 
a day) or doxycyciine (l 00 mg, oraHy, twi«e a day) 
for 14 days. An acute febrile reaction called the 
Jarisch·H~rxheiml!r reaction can occur within 24 
hours of initiating treatment; this is typically seen in 
· · ··· ', · ··-~ ' · ''l' . j b ' · · --~·d w>•h pahents Withe~,~ sypn ~ ,s anu can t: man<tge . ••• , 
antipyretics. Se~ the CDC STD Ciuidelines (20 1 0) fnt 
managen1e n.t of syphHls including neurosyphilis, 
tertiary syphili.~, lat~nt syphiLis, and congenital 
syphilis. 
Homosexuality and STI>s 
in adolescents 
Homosexual hqhavior rnay occur during adolescence 
and eventually, ~- to 6% of adults wl!l identif,Y 
themselves as gay, le.s!an, or bisexuaL Young 
adolescents may only .filld homosexual contact at 
nubile places wh<;'!re pmblems with sexually 
~ransmlrt~d dL;eases (including HIV infection) often 
exist 
Lesbian teens may have sex w ith males as part of 
their adolescent sexual experimentation and some are 
at increased risk of HTV infection as well as other 
STUs b~ausc of coitus with infected males; 
pregnancy risks also occur in this situation if 
unprotected sex occurs. 
" About 25% of those with lilV/AIDS in the 
lbited States contracted their infection by the age of 
21 ye<n·s. For these in tl1eit twenties with HTV. many, 
if nnt most of thM1; wetc infected while they were 
still teenagers .or in thtlir e•1rly twenties (see lhc next 
scc:tion). Even if tlu: adole.sc.cnt engages in same-sex 
behavior for economic reasor\s and not because of 
being homoc'>exual, risks f()r STDs remain. Advice 
r'·'•.rrFdin!!. testing for sexually transmitted diseases ~ "'-'f,. ..A. .... . Q 
includes explaining possible risk factors, treatment 
options, and discussion regarding confidentiality as 
well as intOqning the adolescent's parent, if possible. 
Advice regarding options for self protection 
includes safe sex llwareness and practke, including 
sexual abstinence <>.nd use of Jatex condoms, In 
addition, the adolescent can he taught techniques to 
handle peer pressure r~;:g(l.rding sexual behavior. 
'1111\T'''.,,.-
i:l:;:!:i:':i··· 
·=::::::~r:;::::: ::: 
)I~~~~~u-:: :: · 
1: 
·::::;::s::·::: 
::·:;::s::·::: 
This artide was supplied to you by Children's Mercy Hospitals & C linics' Health Sciences Library 
NOTICE: The U.S. copynght law (Trtle 117 U.S. Code) governs reproduction of copynghted material. The person 
receiving this article is liable for any Infringement of this law. 
Sexuctl(v mlnsmirted diseases 397 
The gastrointestinal trad can h~ invofved \Vlth 
acquisition of STD agents in rectal (receptive} sexulil 
activity. Proctitis (rectal inflammation) is noted with 
anoredal pain, retial discharge, and tenesmus due to 
N gonorrhoeae, T pallidum, HSV, C trachomatitis 
(induding LGV scrovars), and others. In proctocolitis, 
there is abdom]nal cramping, diarrhea, and symptoms 
of rectal intlanimation due to various agents (Table 
19). 
In enLent1s due to various opportumst1c agents 
(Table 20), there is mainly abdominal cramping and 
diarrhea; giardia l:nnblia is the most common cause in 
this sin1ation. 
Tr~atmcnt depends on the causatiw <J.gent(s). In 
proctitis suspected to be due to N. gonorrhoeae 
treatment is with ceftriazone (250 mg [M) and 
doxycycline (100 mg orally, twice a day for 7 days) to 
cover C. trachomatis. Consider herpes and LGV 
scmvars a~ causative of rectal ukcrs and treat 
acco;·dingly; use 3 weeks of doxycycline (TOO rng 
ora1ly, twice a day) for LGV treatment Sec the 20!0 
CDC STD Management Gu.iddines (1). 
Iluman Immunodeficiency Virus/Acquired 
.Immunodeficiency !';)ndrome (l!IV/AJDS) 
Ovt~rail, 1 rnHH.on individuals are t~~timated to be 
infeded with the human immunodeficiency virus-1 
(HJV -1) in the "United States with at least one-third 
seen in those 15 to 29 years of age; approximately 
half of new infections are found in those under age 
25. HiV-2 is prevD.l<)llt in West Africa. Minority 
populations suffer dispropc}rtionatdy higher numbers 
of H.lV infection. This virus ls transmitted via .:>~xual 
activity, needle sharing, and aiso in breast milk. 
The main mode of transmission in tna1es lwving 
HIV 1s males having s~Cx with males (MSM) often 
'v<iith injection drug use, though it can affect any 
gender or age group that is exposed. The introduction 
of z1drn'udine (formerly caned azidothymldLne 
[_abbreviated AZTj) has greatly reduced mother-to-
child tranc;mission atthis time. 
Primary risk categories in adolescent females and 
young \Vomen for HIV infection include heterosexual 
bdsavior complicated by injection dmg use. Another 
group of HIV-infected adolescents is those who were 
infected prenatally awi a(e now in the adolescent age 
group. 
Testing inv()!ves t~se of the HIV EIA/Westcrn 
Blot and should be done a!;cordi;lg to lo;~al statt: 
guidelines for mv testing ( 1 ). 
Generally antibody testing initiates with a. 
screening test such a.s an enzyme immunoassay (EIA) 
and then reactive screening tests are cnnfirrned with a 
test s:uch as the Western Biot test or 
LmmnnoftuorcSC(\nCC a%ay err A). 
A continued positive test )ndicates the individual 
is infected with this virus (HTV) ard can infect others. 
Seroconversion usual.ly occurs within 3 months aftm' 
infection but may take up to 12 mont.1s; a negative 
testing scheme does not rule out a recent infection. 
Plas.ma EIV RNA testing {plasma viral IGad test or 
PVL test) can be obtained in situations when a patient 
has symptomatoicgy consistent \Nlth acute HlV 
infection but HTV antibody testing is negative or 
inconclusive. The RNA viral load test mcasure.s the 
amount of free HTV virus (non cell bound) in the 
infected person.. Follow-up testing (i.e., WGstern Blot) 
can be done in two to four months t0 .:-onfirm HIV 
infection if tbc pia~ma mv piasma testing indicates 
HIV infection. 
Though most newly diagnosed patients are 
asymptomatic, some can develop acute rctrov.[ral 
syndrome (ARS) 2 to 6 \veeks after HlV infection 
before f{fV tcsdng becomes positive. A variety of 
symptoms are noted including fever, malaise, skin 
rash. and lymphadenopathy. 
These youtll may benefit from early usc of anti--
HlV medications (antitretroviral drugs) and should be 
rcfct(ed to local experts in HlV management The 
patient with AIDS has the development of an 
oppt!tiurdstic infection (jr A IDS· defining ailment ih 
one infected v.'ith HIV or a drop in the patient's CD4 
lymphocyte count to 200 ceUs/mm3 or less. 
Thos(: with Hl V /AIDS develop a vvid.e, protean 
variety of potential symptomatology and disorders 
including generalized lymphadenopathy, 
hepatomegaly, splenomegaly, failure to thrive, oral 
thrush, recurrent diarrhea, hepatitis, parotltls, 
c:ardiomyopathy, nephropathy. c:enlral nervous system 
disease, Iy1:nphoid interstitial pnccunonla {UP), 
recurrent invasive bacterial infectJ(Jn:;;, opportunistic 
infections, and malignant neoplasms. 
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Antiretroviral (ART) management 1s 
recommended for all those with HIV and A1DS and 
referral to local experts in an HIV//\IDS cemel' is 
recmimJendcd. to ensure the best treatrnen.t t~;r thi.; 
very complex ~ituation with ever-changir.g protocols 
at'"lJ recommendations, Detailed discussion of 
manage;ncm is beymid the scope ofthis article. 
~--ur.eili-ri-t-:-is ________ ................ -......................... ----------............................................................................................................................ . 
i 
f 
: 
: 
' i 
Neissaia gonorrhoeae 
Chlarnyci;(J tradwmatis 
,1yf_vcoplasma genitalium 
Ureaplasma urea!yticum 
i 
i 
i 
i 
i Trichomonas vagina/is 
i i Herpes Simplex Virus 
! J~dcnov~ru~es 
Pharyngitis 
Neisseria gonorrhoeae 
! 
! 
! 
~ 
i 
! Herpes ,'hmplex Virus 
! 
! 
' 
Treponerru"l pr;lllrlum 
Others 
! 
i,,,',,,_ Acquired immunodeficiency syndrome or AIDS (persons wi:th l·UV i.ntection may acqu1re v<>rious other 
opportunistic infections not listed) 
Genital warts (infection with human papillomavirus [HPVD 
Ectoparasites (Pthl:tus pubis; Sarcoptes scabzei) 
Hepatitis 
Hepatitis A, B, C, D, andior E virus 
Cytomcgaloviru5 
Epste[n-l:.larr virus 
Ulcerative lesions 
Syphilis (Treponema pallichrm) 
Herpes simplex virus (HSV) 
Chancroid (Haemophilvs dv.creyi) 
Lymphogra.nuloml.l venereum (Chlamydia trachomatis) 
Gram.tloms. inguinale (Klebiella granufomatis) 
Enteritis/proctocn litis 
Giardia la.rnbli.a 
S'alnwnelia enteritidis 
Entamoeba histolytica 
Cryptosporidium species 
Campy!t>bacter species 
Shigellr1 species 
! 
I 
! 
' i 
! 
! 
Chlamydia tnzcho.rnatis j 
LGV serovars J 
• _ , , ~ , , , i"' _. _ ~~~~~~.~-....~ _ i , , , .... ~a ~ _• • _ ~""':,~~.-.. ~--~u··--_---·--;--::~----·------·~•••••·-.---,~·••i••••·~·;···~.:::··········-~·-········:-! 
*Repnmea w~th pcrm;sswn rrcm: l_khavtoral Pedtatncs., <.. E dtt<OH. LGitors: Db bn:ydan.u:>, DR Pate;, h;) c·ratt, JR Ca:les 
JR. NY : iUniverse, p3ge 456, 2006. 
This artide was supplied lo you by Children's Mercy Hospitals & Clinics' Heall l1 Sciences Ubrary. 
NOTICE: The U.S. copynght law (Trt le 117 U.S. Code) governs reproduc~on of copyrighted material. The person 
receiving this article is liable for any Infringement of thiS law. 
Sexually transmitted diseases 399 
Table 20. AnHretroviral Mcrlh~~~ti~ns (Par-tial Ust) 
r-:;:--·---·--·······················----·-·<-······----····························-·-·-:--·-·-·-·-·-·----- -------·-·-··--···--·-----·--··-·······---·--·······--··-·-· 
A. Nomiudeo~ide Rever~e Tnmsc.ri.ptasc Iuilibitm·s (NNRI1s) 
Efavi.renz 
Nevirapine 
Dctaviridine 
Etraviri.n.c 
Ri lpi virine 
B. Protea§e Inb:ibitQr S (Pis) 
Atazanavi.r 
Danmavir 
Fosamprenav :r 
Lopinavir 
Saquinavir 
Tipnmavir 
Ritonavit 
Indin.avir 
Ne!finavir 
C Nucleoside Reverse Tra11script8se lnhlbitun• (1\iRTls) 
Ahacavir 
Emtrlc!tabine 
Larnivudine 
Tenofovir 
Zidbv~:dinc 
Didanos.ine 
Stavudine 
D. futeg:raise Strand T:nmsfel:' lnhH:ritor (ISTE) 
Ra.ltegr<Jvir 
E. Cellu.!ar Chemokinc Receptor 5 A~tagomst (CCR.~ A.tltagonist) 
Maravlroc 
:.__ ___________ , ..................................................................... ~------
AutiTetrovirai medications are generally divided into 
t.ive diffcrc.r.t groups (Table 20) and ways to improve 
adherence tc this regimen are listed in Table 2L 
Detalled instructions arc provided at 
ww\~·. aidsinfo.ni.h.gov and it is vital to provide a 
program with \Vell-t;~ined health care prof~~ssiona1s 
who adhen; to up-d<.Ued _protowls. T'he 1ncdications 
al'e compiex with many side effects and drug 
interactions. 
Compi.icat!ng r.he overall treatment is the many 
potential oppnru.mistic infections that may be seen 
that can be dinicuit to treat. ·rhe patient should rnakc 
a commitment to a lifetime of treatment that will 
result in the best possible life span and quality of Hfc, 
especially as t1.eW discoveries are made with rcsenrch 
now and in the future. 
Classification is based p!·edominantly on the CD4 
count and ditJercnt protocols may be used ha.sed on if 
the palit:nt has or has not i·eceived. ART (ART-nai've 
versus ART -expcdcncd); anot:\er import.ant factor is 
the plasma HlV RNA load. Genotype tesling is 
recommended to op1imizc regimen selection due to 
the potentia! Dx drug resistance, 
Ea1·1y ART treatment helps to protect the pathmt'!:i 
sex partner from becoming intected with HIV; correct 
condom usc with aU coitus js alsG important in this 
preventive scheme. Combinatior;, of ARTs is more 
effective than monothcrapy and protocols g.cncra..lly 
use 3 antiret:-ovira! drug.!.-~ frorn. twc) different ;;J<J..s:>e~ , 
sueh a~ including 2 N'RTls along with a protease 
inhibitor or 'Nl\JRTI (Table 20) . 
fr: dividnalizing therapy is essential a11d attempts 
are made to simplifY the treatment protowl to 
maximize compliance with the treatment protocols 
(Table 2 1). 
. ~: 
:·: 
.; . 
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Tabil! 21. Strateg~es to Impr.ove Adh~-~·ence to Antiretrovb·al Thera·py Strat~:gies: 
.From .http://www.aidsinfu.nih .gov/Content.Filcs/Adu!taudAdokscentGL.PJ)K Asse..o;sed May 12,2011. Tal>le i:z 
r:-l=-Ts_e_a_m_u-=ltidi·~-~if;l"i~a~y-t~in1appr-oac:h·-----------------.,-. -N-u:-,r-s-es-,-s-o-cia-lw"Z;;:k;[~, pharrnaci~ts, a~~T~:-edication -l 
Provide an accessible, tn1sting. health care team \ Immagers ---------------------- ------------------------1 
· Es_:~~)~~~h:~:~~~~I~i~~:~~~i~~~~ir~~:i1~jE~::P.~~~nt --------------------------- -----------------------------------------------I 
Establish readiness to start ART j 
ldcnti ry potential ba•riers to adJ:crcnce prl()I' to--T·~·-p-;~y-(:"i~~;;~;;·;;~-ris~~;~-~-------···············-
starting ART J • Active substance r,buse or at high risk of rdapse 
! • Low literacv level 
',· ' ! • Busy daily sd~Qduk and/or travel away from home 
• La-ck of disclosure ofH1V d[il.gnosis 
• Sb;nicism abotltART 
• Lack of prescrlption drug coverage 
--·········- -·;·R_~-f~-~~~-fo~·m;n-ta"Ci~ca.ith aJ-'1--:d-i O-"r:...s_u--:1-}S_ta_· 1-lc--e-abc:--_l-l.-Se-. _tr_e_a_tm-en_:_t .......; .t1·cvide resources for the patient 
• Res.ourves to obtain _prescription dmg coverage 
• Pillboxes 
-ln v.ol ve the-patie1£jj_1-antiretrov lral (AR V')""-········· ··;·j::~~r·~·aa;·;_~pJ;;;·:·r~~:~e·w--p~;t~~nt ial side effects, dosiog 
regimen se1ectiPl1 frequency, pill b:.u-dGn, storage. req1Jiremen:ts, food 
i requirements, and consequences of non--adl1erence 
----........,,...-,,....-~----- - ·· · ·· ··· <···-········· ···············································-------·--··------:- ---:---:-----l 
Assess a:dhcrcncc at cvct·y clinic visit 1,, • Use a simple checklist the patien~ l)att <;omplcte in the 
waiting room 
i " ffave ott~er 1nen1be-rs of the hea1th cart~ · t~an1 also. assess 
i adherence 
j 
1 • Ask the patient open--ended questions (e.g., In the fast 3 days, 
t······················---------·-································---· 
l identify t...i-te type of non .. ~dhcrencc, 
l please tell me how ymi took your medicines.) . 
• Failure to fjll tbc pre:scription(s)-··--···········-·································------···l 
1 
j 
j 
> •••••••••••••••••••• ,.,_. ___ ._,.,..,. w--"•• 
i Identify reasons for nonadherenc~ ; assess and 
j simp !i fy regimen, if poss iblc 
: 
l 
i 
I 
I 
I 
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Conclusion 
1 
• Faiiurc t.o take the right dost~(s) at t."lerigi1t time(s) 
t:~::;:~:;~~~;::~~~~;i:.~:~::~~~:;::;.:,:; I· Difficulty swallowing large pilis 
! • I;orgetfulness 
j • Failure to unden;tand dosing instructions 
i • lna.deq;1ate understandL'1g of (.h~Jg n::si.stam;.e and. its 
I . ' 
i n:latior:sh.ip to adherence 
! ! • Pill fatigue 
: • Other potential barriers {see list_~!~~-':~2 ....................... ·-----~----~---· · 
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High rates of unprot.ccted sexueJ behavicr in 
adolescents result in n1rHions of sexually lnHJsmittcd 
diseases (STDs) h the world. This paper reviewed 
fc1.ctors iJJ.ducing .high STD rates, specific STDs, and 
their management ba~ed on 2010 US Centers for 
Disease and Prevention (CDC) ST.D guidelines. 
CHn!:,:ians should screen all their sexually active 
adolescent patients for STDs and provide preventive 
educa.ti.on as wdi as treatment measures. 
This paper is an adapted version of a chapter in tb~ 
book "Adolescent medicine: Phaq_nacotberapeutics in 
general, mental and ~exual h,,~alth., edited by Donald E 
Grcydanus, Dilip R Patel, C~mthia Feucht, Hatirtl A 
Omar, Jmw Mer-rick and publ ished with pc:rmissi0n 
by Walrct d.c Gruytcr, Berlin and New York. 
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